RARE

3 tracked RARE trades across two active quarters

RARE, Ultragenyx Pharmaceutical Inc., has 3 tracked trades involving 2 distinct traders from January 11, 2022 through September 29, 2026. The activity consists of 1 buy and 2 sells, so sells represent two of the three disclosed transactions. The record is concentrated in only two quarters: 2 trades in 2022 Q1 and 1 trade in 2026 Q3. No activity outside those quarters is included in the provided data.

The quarterly direction changed across the period. Both transactions in 2022 Q1 were sells, with 0 buys reported for that quarter. The single transaction in 2026 Q3 was a buy. Because the full history contains just 3 trades by 2 traders, the sample is too small to support broad conclusions about sentiment toward this healthcare and biotechnology company.

1 buyer accounts for the full disclosed buy activity

Gilbert Cisneros is the only identified buyer in the provided record, with 1 RARE purchase, most recently on September 29, 2026. That one transaction represents all tracked buying in RARE and all activity shown for 2026 Q3. The facts do not identify the sellers or provide transaction sizes, so comparisons among traders or between bought and sold dollar values cannot be made from this dataset.

6 other tickers appear in the buyer’s activity

The RARE buyer also bought AMD, CRWD, HLI, ON, TYL and AGIO. Each overlap involves 1 buyer—the same count as RARE’s total buyer population. With only one RARE buyer, these co-purchases describe a single person’s disclosed activity rather than a recurring pattern across multiple buyers.

Disclosure timing and valuation limits matter: congressional transactions can be reported with a lag of up to 45 days, so the disclosure date may trail the actual trade. When transaction values are presented as filing ranges, dollar amounts are estimates rather than exact figures. No amount ranges were provided here, and the small sample further limits interpretation.